09:52 AM EST - Intellipharmaceutics International Inc. : announced successful results of an initial Phase I clinical trial of a controlled-release pregabalin formulation. We also announced an update to the 2012 goals of our Rexista™ abuse-deterrent formulations for oxycodone, and an update to the development activities of our generic version of Focalin XR. Intellipharmaceutics International Inc.
shares T.I are trading unchanged at $1.81.
